BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

  • STATUS
    Recruiting
  • sponsor
    Bayer
Updated on 23 November 2020

Summary

BAY-94-8862/16244 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Description

Demonstrate whether, in addition to standard of care finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure , a sustained decrease of eGFR ≥ 40% from baseline over at least 4 weeks or renal death

App 3.25 years on study drug.

Details
Clinical Study IdentifierTX144558
SponsorBayer
Last Modified on23 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 0 yrs?
Gender: Male or Female
Written informed consent signed before any study-specific procedure
Men or women aged 18 years and older. The lower age limit may be higher if legally required in the participating country
Women of childbearing potential can only be included in the study if a pregnancy test is negative at the Screening Visit and if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: FSH levels > 40 mIU/mL and estradiol < 20 pg/mL] or have had surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy
Subjects with type 2 diabetes mellitus as defined by the American Diabetes Association
Subjects with a clinical diagnosis of DKD based on either of the following criteria at the
Run-in and Screening Visit
Persistent high albuminuria defined as UACR of ≥ 30 mg/g (≥ 3.4 mg/mmol) but < 300 mg/g (< 33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR ≥ 25 but < 60 mL/min/1.73 m 2 (CKD-EPI) (36, 37) and presence of diabetic retinopathy in the medical history
Persistent very high albuminuria defined as UACR of ≥ 300 mg/g (≥ 33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR ≥ 25 but < 75 mL/min/1.73 m 2 (CKD-EPI)
Note: One re-assessment of eGFR and UACR is allowed at the Run-in Visit and the Screening Visit. If one of the 3 UACR measurements is missing but the other 2 are valid, these values can be used to assess subject’s eligibility for this study
Note: The number of subjects with high albuminuria and presence of diabetic retinopathy in the medical history will be capped at approximately 10% of the total population at screening
Note: The number of subjects with eGFR ≥ 60 to 75 mL/min/1.73m 2 and very high albuminuria will be capped at approximately 10% of the total population with very high albuminuria at screening
Inclusion criteria Cont
Prior treatment with ACEIs and ARBs as follows
For at least 4 weeks prior to the Run-in Visit, subjects should be treated with either an ACEI or ARB, or both
Starting with the Run-in Visit, subjects should be treated with only an ACEI or ARB
For at least 4 weeks prior to the Screening Visit, subjects should be treated with the maximum tolerated labeled dose (but not below the minimal labeled dose) of only an ACEI or an ARB (not both) preferably without any adjustments to dose or choice of agent or to any other antihypertensive or antiglycemic treatment
Serum potassium ≤ 4.8 mmol/L at both the Run-in and the Screening Visit
Note: One re-assessment of potassium is allowed at the Run-in and the Screening Visit
Ability to understand and follow study-related instructions

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study
Medical and surgical history
Known significant non-diabetic renal disease, including clinically relevant renal artery stenosis
UACR > 5000 mg/g (> 565 mg/mmol) at the Run-in Visit or Screening Visit
HbA1c > 12% (> 108 mmol/mol) at the Run-in Visit or Screening Visit
Uncontrolled arterial hypertension with mean sitting systolic blood pressure >(SBP) 170 mmHg or mean sitting diastolic blood pressure (DBP) >110 mmHg at the Run-in Visit or mean sitting SBP >160 mmHg or mean sitting DBP >100 mmHg at the Screening Visit
SBP < 90 mmHg at the Run-in Visit or at the Screening Visit
Subjects with a clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class II - IV) at the Run-in Visit (class 1A recommendation for MRAs)
Stroke, transient ischemic cerebral attack, acute coronary syndrome, or hospitalization for worsening heart failure, in the last 30 days prior to the Run-in Visit
Dialysis for acute renal failure within 12 weeks prior to the Run-in Visit
Renal allograft in place or a scheduled kidney transplant within the next 12 months from the Run-in Visit
Known hypersensitivity to the study treatment (active substance or excipients)
Addison’s disease
Hepatic insufficiency classified as Child-Pugh C. Medication and drug use
Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic which cannot be discontinued at least 4 weeks prior to the Screening Visit
Concomitant therapy with both ACEI and ARBs which cannot be discontinued for the purpose of the study
Concomitant therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors or inducers (to be stopped at least 7 days before randomization)
Any other condition or therapy, which would make the subject unsuitable for this study and will not allow participation for the full planned study period (e.g. active malignancy or other condition limiting life expectancy to less than 12 months)
Pregnant or breast-feeding or intention to become pregnant during the study
Previous assignment to treatment during this study or Studies 17530 or 16275
Previous (within 30 days prior to randomization) or concomitant participation in another clinical study (i.e. Phase I-III clinical studies) with investigational medicinal product(s), except for participation in the Run-in and Screening period of Study 17530
Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g. employee or student of the investigational site)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note